Circulating free DNA concentration is an independent prognostic biomarker in lung cancer

Tissot Claire, Toffart Anne-Claire, Villar Stéphanie, Souquet Pierre-Jean, Merle Patrick, Moro-Sibilot Denis, Pérol Maurice, Zavadil Jiri, Brambilla Christian, Olivier Magali, Couraud Sébastien

Source: Eur Respir J 2015; 46: 1773-1780
Journal Issue: December
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Tissot Claire, Toffart Anne-Claire, Villar Stéphanie, Souquet Pierre-Jean, Merle Patrick, Moro-Sibilot Denis, Pérol Maurice, Zavadil Jiri, Brambilla Christian, Olivier Magali, Couraud Sébastien. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J 2015; 46: 1773-1780

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008


Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker?
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008


Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012

Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Source: Eur Respir J 2015; 46: 1548-1550
Year: 2015


Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004

Serum tumor markers in lung cancer patients
Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies
Year: 2007


Evaluation of serum tumour markers in the lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002

Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010



Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003

Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 250s
Year: 2003

Serum angiopoietins as a clinical marker for resected early lung cancer
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


The detection of quantitative serum p53 protein in lung cancer and its clinical value
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003

Is neutrophil/lymphocyte ratio at the time of diagnosis a valuable prognostic factor in non-small cell lung cancer?
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018

Analysis of surgical stage lung cancer and tumour markers prognostic value
Source: Eur Respir J 2006; 28: Suppl. 50, 770s
Year: 2006

Circulating total leptin as a diagnostic and prognostic biomarker in sepsis
Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Year: 2019


HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Telomerase activity as a prognostic marker in non small cell lung cancer
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008


Elevated serum levels of oxidative stress biomarkers in patients with lung cancer
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010